Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adicet Bio, Inc. (ACET)
USD8.74
-0.09 (-1.02%)
US NASDAQ Healthcare Biotechnology
Address
200 Clarendon Street 2116
Boston, MA, US
Boston, MA, US
CEO
Chen Schor
Website
adicetbio.com
IPO
2018-01-26
CIK 1720580 ISIN US0070022076
Also trades on
London Stock Exchange · 0HX7.L (USD)
NASDAQ Global Market · ACET (USD)
Description
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| resTORbio | TORC | 2020-06-23 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.74
-0.09 (-1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
115.2K
Beta
1.59
Float Shares
8.45M
Free Float %
88.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.69% | -7.02% | +17.60% | +18.30% | -27.60% | -5.58% | -31.11% | -92.19% | -96.23% | -99.58% | -99.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
8.74
Low
18.00
+105.9%
Consensus
18.00
+105.9%
Median
18.00
+105.9%
High
18.00
+105.9%
DCF (Unlevered)
2.93
-66.5%
DCF (Levered)
3.51
-59.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
18.00
+105.9%
|
| All Time | 3 |
352.67
+3,935.1%
|
Quality scores
Altman Z-Score
-4.32
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+20.4% Q1'26: +62.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-792.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.5% Q1'26: +88.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q1'26: -0.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.90M
est: 12.50M (+43.3%)
|
9.73M
est: 8.18M (+18.9%)
|
24.99M
est: 35.40M (-29.4%)
|
—
est: 555.6K (-100.0%)
|
—
est: 1.67M (-100.0%)
|
—
est: 2.86M (-100.0%)
|
2.86M
2.86M – 2.86M
+0.0% YoY
|
42.78M
42.78M – 42.78M
+1,397.4% YoY
|
112.62M
112.62M – 112.62M
+163.2% YoY
|
170.59M
170.59M – 170.59M
+51.5% YoY
|
349.65M
349.65M – 349.65M
+105.0% YoY
|
| EBITDA |
-37.41M
est: -2.50M (-1,396.7%)
|
-60.41M
est: -1.64M (-3,590.6%)
|
-64.70M
est: -7.08M (-813.9%)
|
-136.54M
est: -111.1K (-122,781.6%)
|
-110.65M
est: 333.3K (-33,295.0%)
|
-115.73M
est: 571.4K (-20,353.3%)
|
571.4K
571.4K – 571.4K
+0.0% YoY
|
8.56M
8.56M – 8.56M
+1,397.4% YoY
|
22.52M
22.52M – 22.52M
+163.2% YoY
|
34.12M
34.12M – 34.12M
+51.5% YoY
|
69.93M
69.93M – 69.93M
+105.0% YoY
|
| EBIT |
-39.36M
est: -2.50M (-1,474.8%)
|
-61.95M
est: -1.64M (-3,684.5%)
|
-69.71M
est: -7.08M (-884.7%)
|
-142.63M
est: -111.1K (-128,269.8%)
|
-117.12M
est: 333.3K (-35,235.4%)
|
-122.11M
est: 571.4K (-21,470.0%)
|
571.4K
571.4K – 571.4K
+0.0% YoY
|
8.56M
8.56M – 8.56M
+1,397.4% YoY
|
22.52M
22.52M – 22.52M
+163.2% YoY
|
34.12M
34.12M – 34.12M
+51.5% YoY
|
69.93M
69.93M – 69.93M
+105.0% YoY
|
| Net Income |
-36.68M
est: -312.80M (+88.3%)
|
-62.00M
est: -168.12M (+63.1%)
|
-69.79M
est: -111.20M (+37.2%)
|
-142.66M
est: -290.74M (+50.9%)
|
-117.12M
est: -174.68M (+33.0%)
|
-116.80M
est: -111.41M (-4.8%)
|
-67.96M
-76.71M – -59.22M
+39.0% YoY
|
-23.00M
-23.00M – -23.00M
+66.2% YoY
|
-81.03M
-300.52M – 702.65M
-252.3% YoY
|
46.03M
46.03M – 46.03M
+156.8% YoY
|
95.40M
95.40M – 95.40M
+107.2% YoY
|
| SGA |
22.76M
est: 16.51M (+37.8%)
|
22.22M
est: 10.82M (+105.5%)
|
26.30M
est: 46.77M (-43.8%)
|
26.53M
est: 734.1K (+3,514.2%)
|
28.29M
est: 2.11M (+1,239.6%)
|
22.99M
est: 3.62M (+534.9%)
|
3.62M
3.62M – 3.62M
+0.0% YoY
|
54.21M
54.21M – 54.21M
+1,397.4% YoY
|
142.70M
142.70M – 142.70M
+163.2% YoY
|
216.17M
216.17M – 216.17M
+51.5% YoY
|
443.07M
443.07M – 443.07M
+105.0% YoY
|
| EPS |
-80.16
est: -3.56 (-2,151.7%)
|
-32.00
est: -1.91 (-1,572.5%)
|
-27.20
est: -1.27 (-2,049.2%)
|
-52.96
est: -3.31 (-1,500.5%)
|
-21.28
est: -25.44 (+16.4%)
|
-16.95
est: -16.17 (-4.8%)
|
-9.86
-11.13 – -8.59
+39.0% YoY
|
-3.34
-3.34 – -3.34
+66.2% YoY
|
2.37
-43.61 – 101.96
+170.9% YoY
|
6.68
6.68 – 6.68
+182.3% YoY
|
13.84
13.84 – 13.84
+107.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-95.25M
OE per share TTM
-16.09
Owner's Yield
-169.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
413.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
4.38M
Insider transactions (90d)
1
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 7.70M | 9.99% | — | 7.70M | — | 7.70M | HC, IN | Delaware | 2024-02-05 | ↗ |
| 2 | RA Capital Healthcare Fund, L.P. | 7.70M | 9.99% | — | 7.70M | — | 7.70M | PN | Delaware | 2024-02-05 | ↗ |
| 3 | RA Capital Management, L.P. | 7.70M | 9.99% | — | 7.70M | — | 7.70M | IA, PN | Delaware | 2024-02-05 | ↗ |
| 4 | Rajeev Shah | 7.70M | 9.99% | — | 7.70M | — | 7.70M | HC, IN | Delaware | 2024-02-05 | ↗ |
| 5 | OrbiMed Capital GP V LLC | 5.24M | 13.40% | — | 5.24M | — | 10.00 | OO | Delaware | 2021-12-14 | ↗ |
| 6 | Capital LP | 4.25M | 9.80% | — | 4.25M | — | 4.25M | IA | Delaware, USA | 2024-01-19 | ↗ |
| 7 | Capital Master LP | 4.25M | 9.80% | — | 4.25M | — | 4.25M | OO | Delaware, USA | 2024-01-19 | ↗ |
| 8 | Israel A. Englander | 3.95M | 5.20% | — | 3.95M | — | 3.95M | IN | Delaware | 2024-02-27 | ↗ |
| 9 | Millennium Group Management LLC | 3.95M | 5.20% | — | 3.95M | — | 3.95M | OO | Delaware | 2024-02-27 | ↗ |
| 10 | Millennium Management LLC | 3.95M | 5.20% | — | 3.95M | — | 3.95M | OO | Delaware | 2024-02-27 | ↗ |
| 11 | EcoR1 Capital, LLC | 3.56M | 11.00% | — | 3.56M | — | — | IA, OO | Delaware | 2022-12-23 | ↗ |
| 12 | Oleg Nodelman | 3.56M | 11.00% | — | 3.56M | — | — | HC, IN | Delaware | 2022-12-23 | ↗ |
| 13 | EcoR1 Capital Fund Qualified, L.P. | 3.35M | 11.00% | — | 3.35M | — | — | PN | Delaware | 2022-12-23 | ↗ |
| 14 | Avidity Capital Partners (GP) LLC | 3.03M | 7.90% | — | 3.03M | — | 3.03M | OO | — | 2022-02-14 | ↗ |
| 15 | Avidity Capital Partners Fund (GP) LP | 3.03M | 7.90% | — | 3.03M | — | 3.03M | PN, OO | — | 2022-02-14 | ↗ |
| 16 | Avidity Partners Management (GP) LLC | 3.03M | 7.90% | — | 3.03M | — | 3.03M | OO | — | 2022-02-14 | ↗ |
| 17 | Avidity Partners Management LP | 3.03M | 7.90% | — | 3.03M | — | 3.03M | IA, PN | — | 2022-02-14 | ↗ |
| 18 | David Witzke | 3.03M | 7.90% | — | 3.03M | — | 3.03M | IN | — | 2022-02-14 | ↗ |
| 19 | Michael Gregory | 3.03M | 7.90% | — | 3.03M | — | 3.03M | IN | — | 2022-02-14 | ↗ |
| 20 | RTW Investments, LP | 3.02M | 7.91% | — | 3.02M | — | 3.02M | IA, OO | Delaware | 2021-12-15 | ↗ |
| 21 | Roderick Wong | 3.02M | 7.91% | — | 3.02M | — | 3.02M | HC | Delaware | 2021-12-15 | ↗ |
| 22 | Morgan Stanley | 2.78M | 6.40% | 13.00 | 2.78M | — | 13.00 | HC, CO | — | 2024-02-12 | ↗ |
| 23 | (1) BlackRock, Inc. | 2.55M | 5.90% | 2.47M | — | 2.55M | — | HC | Delaware | 2023-02-13 | ↗ |
| 24 | Avidity Master Fund LP | 2.42M | 6.30% | — | 2.42M | — | 2.42M | PN, OO | — | 2022-02-14 | ↗ |
| 25 | STATE STREET CORPORATION | 2.28M | 5.33% | — | 2.26M | — | 2.28M | HC | BOSTON, MASSACHUSETTS | 2023-02-03 | ↗ |
| 26 | KEVIN TANG | 2.27M | 5.30% | — | 2.27M | — | 2.27M | IN | DELAWARE | 2023-03-13 | ↗ |
| 27 | RTW Master Fund, Ltd. | 2.00M | 5.24% | — | 2.00M | — | 2.00M | CO | Delaware | 2021-12-15 | ↗ |
| 28 | OrbiMed Israel BioFund GP Limited Partnership | 902.9K | 2.30% | — | 902.9K | — | 10.00 | OO | Cayman Islands | 2021-12-14 | ↗ |
| 29 | OrbiMed Advisors Israel II Limited | 396.7K | 1.00% | — | 396.7K | — | 10.00 | IA | Cayman Islands | 2021-12-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-39 vs prev Q
New positions
6
Closed positions
45
Increased
7
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 157.8K +157.8K (+100.0%) | 1.33B +1.3B (+100.0%) | 2.77% +2.772 pp | 0.78% +0.780 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 948.2K +948.2K (+100.0%) | 7.98M +8.0M (+100.0%) | 16.66% +16.657 pp | 0.08% +0.082 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 3 | FRANKLIN RESOURCES INC | 626.6K +626.6K (+100.0%) | 5.28M +5.3M (+100.0%) | 11.01% +11.006 pp | 0.00% +0.001 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 4 | WOODLINE PARTNERS LP | 625.0K +625.0K (+100.0%) | 5.26M +5.3M (+100.0%) | 10.98% +10.979 pp | 0.02% +0.020 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 5 | VANGUARD GROUP INC | 291.3K +291.3K (+100.0%) | 2.45M +2.5M (+100.0%) | 5.12% +5.117 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 274.4K +274.4K (+100.0%) | 2.31M +2.3M (+100.0%) | 4.82% +4.820 pp | 0.00% +0.004 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 7 | PROSIGHT MANAGEMENT, LP | 250.2K +250.2K (+100.0%) | 2.11M +2.1M (+100.0%) | 4.40% +4.396 pp | 0.44% +0.435 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 242.9K +242.9K (+100.0%) | 2.05M +2.0M (+100.0%) | 4.27% +4.268 pp | 0.00% +0.003 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 9 | GOLDMAN SACHS GROUP INC | 234.5K +234.5K (+100.0%) | 1.97M +2.0M (+100.0%) | 4.12% +4.119 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 10 | STONEPINE CAPITAL MANAGEMENT, LLC | 220.0K +220.0K (+100.0%) | 1.85M +1.9M (+100.0%) | 3.86% +3.865 pp | 1.35% +1.353 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 11 | ALYESKA INVESTMENT GROUP, L.P. | 203.8K +203.8K (+100.0%) | 1.72M +1.7M (+100.0%) | 3.58% +3.580 pp | 0.00% +0.005 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 12 | CARLYLE GROUP INC. | 184.3K +184.3K (+100.0%) | 1.54M +1.5M (+100.0%) | 3.24% +3.237 pp | 0.01% +0.011 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 13 | ACADIAN ASSET MANAGEMENT LLC | 181.4K +181.4K (+100.0%) | 1.53M +1.5M (+100.0%) | 3.19% +3.186 pp | 0.00% +0.003 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 14 | TWO SIGMA INVESTMENTS, LP | 144.8K +144.8K (+100.0%) | 1.22M +1.2M (+100.0%) | 2.54% +2.543 pp | 0.00% +0.002 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 15 | ADAR1 CAPITAL MANAGEMENT, LLC | 128.6K +128.6K (+100.0%) | 1.08M +1.1M (+100.0%) | 2.26% +2.260 pp | 0.08% +0.080 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 16 | TWO SIGMA ADVISERS, LP | 111.3K +111.3K (+100.0%) | 937.4K +937.4K (+100.0%) | 1.96% +1.956 pp | 0.00% +0.002 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 17 | CITADEL ADVISORS LLC | 107.8K +107.8K (+100.0%) | 907.8K +907.8K (+100.0%) | 1.89% +1.894 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 18 | DAFNA CAPITAL MANAGEMENT LLC | 93.8K +93.8K (+100.0%) | 789.9K +789.9K (+100.0%) | 1.65% +1.648 pp | 0.18% +0.184 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 88.9K +88.9K (+100.0%) | 748.3K +748.3K (+100.0%) | 1.56% +1.561 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 20 | BURKEHILL GLOBAL MANAGEMENT, LP | 62.5K +62.5K (+100.0%) | 526.3K +526.3K (+100.0%) | 1.10% +1.098 pp | 0.03% +0.035 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 21 | REGENERON PHARMACEUTICALS, INC. | 60.5K -907.7K (-93.8%) | 509.5K -274.9K (-35.0%) | 1.06% +0.000 pp | 1.51% +1.395 pp | USD15.39 -45.3% | 5 qtrs — |
| 22 | LUMINUS MANAGEMENT LLC | 59.6K +59.6K (+100.0%) | 501.5K +501.5K (+100.0%) | 1.05% +1.046 pp | 0.44% +0.439 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 23 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 56.4K +56.4K (+100.0%) | 474.5K +474.5K (+100.0%) | 0.99% +0.990 pp | 0.01% +0.010 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 24 | SQUAREPOINT OPS LLC | 55.7K +55.7K (+100.0%) | 469.2K +469.2K (+100.0%) | 0.98% +0.979 pp | 0.00% +0.001 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 25 | RBF CAPITAL, LLC | 38.6K +38.6K (+100.0%) | 324.9K +324.9K (+100.0%) | 0.68% +0.678 pp | 0.01% +0.014 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 26 | BLACKROCK, INC. | 36.6K +36.6K (+100.0%) | 308.0K +308.0K (+100.0%) | 0.64% +0.643 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 27 | MAVEN SECURITIES LTD | 31.3K +31.3K (+100.0%) | 263.1K +263.1K (+100.0%) | 0.55% +0.549 pp | 0.01% +0.006 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 28 | STATE STREET CORP | 25.9K +25.9K (+100.0%) | 218.0K +218.0K (+100.0%) | 0.45% +0.455 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 29 | RANGELEY CAPITAL, LLC | 25.0K +25.0K (+100.0%) | 210.5K +210.5K (+100.0%) | 0.44% +0.439 pp | 0.17% +0.175 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 30 | BARCLAYS PLC | 25.0K +25.0K (+100.0%) | 210.5K +210.5K (+100.0%) | 0.44% +0.439 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 31 | JOHNSON & JOHNSON | 22.8K +22.8K (+100.0%) | 191.8K +191.8K (+100.0%) | 0.40% +0.400 pp | 0.03% +0.035 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 32 | XTX TOPCO LTD | 18.6K +18.6K (+100.0%) | 156.7K +156.7K (+100.0%) | 0.33% +0.327 pp | 0.00% +0.004 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 33 | GSA CAPITAL PARTNERS LLP | 17.8K +17.8K (+100.0%) | 150.0K +150.0K (+100.0%) | 0.31% +0.312 pp | 0.01% +0.013 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 34 | NORTHERN TRUST CORP | 14.1K +14.1K (+100.0%) | 118.4K +118.4K (+100.0%) | 0.25% +0.247 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 35 | TANG CAPITAL MANAGEMENT LLC | 6.2K +6.2K (+100.0%) | 51.9K +51.9K (+100.0%) | 0.11% +0.108 pp | 0.00% +0.003 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 36 | FNY INVESTMENT ADVISERS, LLC | 6.1K +6.1K (+100.0%) | 51.0K +51.0K (+100.0%) | 0.11% +0.107 pp | 0.01% +0.014 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 37 | ROYAL BANK OF CANADA | 5.4K +5.4K (+100.0%) | 46.0K +46.0K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 38 | UBS GROUP AG | 3.8K +3.8K (+100.0%) | 32.0K +32.0K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 39 | MORGAN STANLEY | 3.0K +3.0K (+100.0%) | 25.6K +25.6K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 40 | BANK OF AMERICA CORP /DE/ | 1.3K +1.3K (+100.0%) | 10.8K +10.8K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 41 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.1K +1.1K (+100.0%) | 9.0K +9.0K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 42 | HOLLENCREST CAPITAL MANAGEMENT | 250.00 +250.0 (+100.0%) | 2.1K +2.1K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 43 | SIMPLEX TRADING, LLC | 87.00 +87.0 (+100.0%) | 732.00 +732.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD8.41 +0.1% | 1 qtrs NEW |
| 44 | BNP PARIBAS ARBITRAGE, SNC | 50.00 +50.0 (+100.0%) | 421.00 +421.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 45 | FMR LLC | 34.00 +34.0 (+100.0%) | 286.00 +286.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD8.41 +0.1% | 1 qtrs NEW |
| 46 | SBI SECURITIES CO., LTD. | 19.00 +19.0 (+100.0%) | 160.00 +160.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.37 +0.6% | 1 qtrs NEW |
| 47 | JPMORGAN CHASE & CO | 12.00 +12.0 (+100.0%) | 101.00 +101.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.42 +0.0% | 1 qtrs NEW |
| 48 | DANSKE BANK A/S | 1.00 +1.0 (+100.0%) | 8.00 +8.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +5.3% | 1 qtrs NEW |
| 49 | SCHONFELD STRATEGIC ADVISORS LLC | — -479.1K (-100.0%) | — -388.2K (-100.0%) | 0.00% -0.526 pp | 0.00% -0.002 pp | USD— | 3 qtrs SOLD |
| 50 | HRT FINANCIAL LP | — -18.6K (-100.0%) | — -15.0K (-100.0%) | 0.00% -0.020 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 51 | DIMENSIONAL FUND ADVISORS LP | — -53.0K (-100.0%) | — -42.9K (-100.0%) | 0.00% -0.058 pp | 0.00% +0.000 pp | USD— | 19 qtrs SOLD |
| 52 | CITIGROUP INC | — -166.0 (-100.0%) | — -134.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 22 qtrs SOLD |
| 53 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -40.4K (-100.0%) | — -32.7K (-100.0%) | 0.00% -0.044 pp | 0.00% +0.000 pp | USD— | 21 qtrs SOLD |
| 54 | QUBE RESEARCH & TECHNOLOGIES LTD | — -20.3K (-100.0%) | — -16.4K (-100.0%) | 0.00% -0.022 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 55 | TOTH FINANCIAL ADVISORY CORP | — -1.6K (-100.0%) | — -1.3K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 56 | JANE STREET GROUP, LLC | — -186.2K (-100.0%) | — -150.9K (-100.0%) | 0.00% -0.204 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 57 | ORBIMED ADVISORS LLC | — -11.4M (-100.0%) | — -9.3M (-100.0%) | 0.00% -12.567 pp | 0.00% -0.219 pp | USD— | 22 qtrs SOLD |
| 58 | ABACUS PLANNING GROUP, INC. | — -36.8K (-100.0%) | — -29.8K (-100.0%) | 0.00% -0.040 pp | 0.00% -0.004 pp | USD— | 3 qtrs SOLD |
| 59 | TWO SIGMA SECURITIES, LLC | — -25.3K (-100.0%) | — -20.5K (-100.0%) | 0.00% -0.028 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 60 | MILLENNIUM MANAGEMENT LLC | — -566.0K (-100.0%) | — -458.5K (-100.0%) | 0.00% -0.621 pp | 0.00% 0.000 pp | USD— | 15 qtrs SOLD |
| 61 | MARSHALL WACE, LLP | — -51.7K (-100.0%) | — -41.9K (-100.0%) | 0.00% -0.057 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 62 | VIRTU FINANCIAL LLC | — -79.9K (-100.0%) | — -65.0K (-100.0%) | 0.00% -0.088 pp | 0.00% -0.004 pp | USD— | 5 qtrs SOLD |
| 63 | VONTOBEL HOLDING LTD. | — -80.0K (-100.0%) | — -65.2K (-100.0%) | 0.00% -0.088 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
| 64 | WEALTHEDGE INVESTMENT ADVISORS, LLC | — -300.1K (-100.0%) | — -243.1K (-100.0%) | 0.00% -0.329 pp | 0.00% -0.092 pp | USD— | 5 qtrs SOLD |
| 65 | ADVISORY SERVICES NETWORK, LLC | — -316.0 (-100.0%) | — -256.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 66 | MARINER, LLC | — -14.9K (-100.0%) | — -12.0K (-100.0%) | 0.00% -0.016 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 67 | RAYMOND JAMES FINANCIAL INC | — -13.3K (-100.0%) | — -10.7K (-100.0%) | 0.00% -0.015 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 68 | ADVISOR GROUP HOLDINGS, INC. | — -10.0 (-100.0%) | — -7.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 211.4K | 0.60% |
| 2 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 130.2K | 0.43% |
| 3 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 37.6K | 0.25% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 900.1K | 0.05% |
| 5 | Dimensional - US Small Cap ETF DFAS | 0.00% | 129.9K | 0.26% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 885.16 | 0.17% |
| 7 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.4K | 0.03% |
| 8 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 12.0K | 0.17% |
| 9 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.05M | 0.03% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.5K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.20
Bearish
Ratio by volume
0.70
Neutral
Buys
1
Sells
5
Shares acquired
250.0K
Shares disposed
354.7K
Cash buys
—
Cash sales
4.00
Net activity
-104,658
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J-Other | A | Pre-Funded Warrant (Right to Buy) | 250,000 | 0.00 | 25.00 | 1,402,833 | I | ↗ |
| 2026-04-08 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 40,416 | 6.52 | 263.5K | 0 | I | ↗ |
| 2026-04-07 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 29,319 | 6.53 | 191.5K | 34,923 | I | ↗ |
| 2026-03-25 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 468,555 | 6.81 | 3.19M | 468,555 | D | ↗ |
| 2026-03-25 | Maltzman Julia D. | Officer | A-Award | A | Stock Option (Right to Buy) | 72,555 | 6.81 | 494.1K | 72,555 | D | ↗ |
| 2026-03-25 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 43,361 | 6.81 | 295.3K | 43,361 | D | ↗ |
| 2026-03-25 | Harvey Brian Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 43,361 | 6.81 | 295.3K | 43,361 | D | ↗ |
| 2026-03-25 | Aftab Blake | Officer | A-Award | A | Stock Option (Right to Buy) | 72,555 | 6.81 | 494.1K | 72,555 | D | ↗ |
| 2026-02-20 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 74,751 | 7.27 | 543.4K | 1,182,624 | I | ↗ |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 74,268 | 7.21 | 535.5K | 1,107,873 | I | ↗ |
| 2026-02-18 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 74,577 | 7.04 | 525.0K | 1,033,605 | I | ↗ |
| 2026-02-17 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | — | Pre-Funded Warrant (Right to Buy) | 1,152,833 | 0.00 | 115.28 | 0 | I | ↗ |
| 2026-01-24 | Schor Chen | Director / Officer | F-InKind | D | Common Stock | 1,755 | 8.44 | 14.8K | 6,820 | D | ↗ |
| 2026-01-24 | Healey Don | Officer | F-InKind | D | Common Stock | 535 | 8.44 | 4.5K | 3,452 | D | ↗ |
| 2026-01-24 | Harvey Brian Nicholas | Officer | F-InKind | D | Common Stock | 546 | 8.44 | 4.6K | 5,145 | D | ↗ |
| 2026-01-24 | Aftab Blake | Officer | F-InKind | D | Common Stock | 535 | 8.44 | 4.5K | 2,981 | D | ↗ |
| 2025-10-08 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 3,500,000 | 1.00 | 3.50M | 4,490,254 | I | ↗ |
| 2025-06-11 | Sinclair Andrew | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 17,700 | D | ↗ |
| 2025-06-11 | Peng Katie | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 11,800 | D | ↗ |
| 2025-06-11 | Klickstein Lloyd | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 108,566 | D | ↗ |
| 2025-06-11 | DUBIN STEVE | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 22,700 | D | ↗ |
| 2025-06-11 | Chodakewitz Jeffrey | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 17,700 | D | ↗ |
| 2025-04-17 | Grissinger Michael | Director | A-Award | A | Stock Option (Right to Buy) | 70,200 | 0.53 | 36.9K | 70,200 | D | ↗ |
| 2025-01-31 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 763,829 | 0.89 | 676.0K | 763,829 | D | ↗ |
| 2025-01-31 | Maltzman Julia D. | Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 0.89 | 663.8K | 750,000 | D | ↗ |
| 2025-01-31 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 0.89 | 243.4K | 275,000 | D | ↗ |
| 2025-01-31 | Harvey Brian Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 324,040 | 0.89 | 286.8K | 324,040 | D | ↗ |
| 2025-01-31 | Aftab Blake | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 0.89 | 243.4K | 275,000 | D | ↗ |
| 2025-01-24 | Schor Chen | Director / Officer | F-InKind | D | Common Stock | 28,101 | 0.92 | 25.9K | 137,201 | D | ↗ |
| 2025-01-24 | Healey Don | Officer | F-InKind | D | Common Stock | 8,560 | 0.92 | 7.9K | 63,769 | D | ↗ |
| 2025-01-24 | Harvey Brian Nicholas | Officer | F-InKind | D | Common Stock | 8,752 | 0.92 | 8.1K | 91,048 | D | ↗ |
| 2025-01-24 | Aftab Blake | Officer | F-InKind | D | Common Stock | 6,270 | 0.92 | 5.8K | 56,241 | D | ↗ |
| 2025-01-13 | Maltzman Julia D. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-21 | Sinclair Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 28,828 | 15.75 | 454.0K | 28,828 | — | ↗ |
| 2024-08-21 | Peng Katie | Director | A-Award | A | Stock Option (Right to Buy) | 70,200 | 3.38 | 237.3K | 70,200 | — | ↗ |
| 2024-08-21 | Kauffman Michael | Director | D-Return | D | Stock Option (Right to Buy) | 26,400 | 2.14 | 56.5K | 0 | — | ↗ |
| 2024-08-21 | Jakobovits Aya | Director | D-Return | D | Stock Option (Right to Buy) | 26,400 | 2.14 | 56.5K | 0 | — | ↗ |
| 2024-08-21 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 26,400 | 5.20 | 137.1K | 26,400 | — | ↗ |
| 2024-08-21 | DUBIN STEVE | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 18,500 | — | ↗ |
| 2024-08-21 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 11.49 | 212.6K | 18,500 | — | ↗ |
| 2024-08-19 | Klickstein Lloyd | Director | A-Award | A | Stock Option (Right to Buy) | 70,200 | 1.55 | 108.8K | 70,200 | — | ↗ |
| 2024-06-05 | Sinclair Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 26,400 | 1.44 | 38.0K | 26,400 | — | ↗ |
| 2024-06-05 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,770,427 | 2.53 | 4.48M | 1,770,427 | — | ↗ |
| 2024-06-05 | Peng Katie | Director | A-Award | A | Stock Option (Right to Buy) | 26,400 | 1.44 | 38.0K | 26,400 | — | ↗ |
| 2024-06-05 | Kauffman Michael | Director | S-Sale | D | Common Stock | 5,900 | 1.43 | 8.4K | 5,900 | — | ↗ |
| 2024-06-05 | Jakobovits Aya | Director | A-Award | A | Stock Option (Right to Buy) | 26,400 | 1.44 | 38.0K | 26,400 | — | ↗ |
| 2024-06-05 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 271,595 | 2.53 | 687.1K | 271,595 | — | ↗ |
| 2024-06-05 | Harvey Brian Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 374,829 | 2.53 | 948.3K | 374,829 | — | ↗ |
| 2024-06-05 | Galimi Francesco | Officer | A-Award | A | Stock Option (Right to Buy) | 375,077 | 2.53 | 948.9K | 375,077 | — | ↗ |
| 2024-06-05 | GORDON CARL L | Director / 10% Owner | A-Award | A | Common Stock | 5,900 | 0.00 | — | 11,800 | — | ↗ |
| 2024-06-05 | DUBIN STEVE | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 16,800 | — | ↗ |
| 2024-06-05 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 26,400 | 1.44 | 38.0K | 26,400 | — | ↗ |
| 2024-06-05 | Aftab Blake | Officer | A-Award | A | Stock Option (Right to Buy) | 336,911 | 2.53 | 852.4K | 336,911 | — | ↗ |
| 2024-01-25 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 1,041,700 | 2.40 | 2.50M | 1,255,985 | — | ↗ |
| 2024-01-25 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 1,841,100 | 2.40 | 4.42M | 7,526,359 | — | ↗ |
| 2024-01-24 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,116,903 | 2.40 | 2.68M | 1,116,903 | — | ↗ |
| 2024-01-24 | Healey Don | Officer | A-Award | A | Common Stock | 19,700 | 0.00 | — | 72,329 | — | ↗ |
| 2024-01-24 | Harvey Brian Nicholas | Officer | A-Award | A | Common Stock | 26,300 | 0.00 | — | 99,800 | — | ↗ |
| 2024-01-24 | Galimi Francesco | Officer | A-Award | A | Common Stock | 26,300 | 0.00 | — | 101,801 | — | ↗ |
| 2024-01-24 | Aftab Blake | Officer | F-InKind | D | Common Stock | 3,565 | 2.40 | 8.6K | 42,811 | — | ↗ |
| 2023-10-12 | Aftab Blake | Officer | F-InKind | D | Common Stock | 7,933 | 1.35 | 10.7K | 46,376 | — | ↗ |
| 2023-10-02 | Schor Chen | Director / Officer | P-Purchase | A | Common Stock | 5,500 | 1.33 | 7.3K | 43,469 | — | ↗ |
| 2023-10-02 | Healey Don | Officer | F-InKind | D | Common Stock | 9,069 | 1.37 | 12.4K | 57,499 | — | ↗ |
| 2023-10-02 | Harvey Brian Nicholas | Officer | F-InKind | D | Common Stock | 7,096 | 1.37 | 9.7K | 77,820 | — | ↗ |
| 2023-10-02 | Galimi Francesco | Officer | F-InKind | D | Common Stock | 8,093 | 1.37 | 11.1K | 80,458 | — | ↗ |
| 2023-09-29 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 5,500 | 1.36 | 7.5K | 176,969 | — | ↗ |
| 2023-09-28 | Schor Chen | Director / Officer | P-Purchase | A | Common Stock | 5,500 | 1.42 | 7.8K | 182,469 | — | ↗ |
| 2023-08-14 | Sinclair Andrew | Director | D-Return | D | Stock Option (Right to Buy) | 26,400 | 5.20 | 137.1K | 0 | — | ↗ |
| 2023-08-14 | Schor Chen | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 872,111 | 16.11 | 14.05M | 0 | — | ↗ |
| 2023-08-14 | Sanna Bastiano | Director | D-Return | D | Stock Option (Right to Buy) | 26,400 | 5.20 | 137.1K | 0 | — | ↗ |
| 2023-08-14 | Peng Katie | Director | D-Return | D | Stock Option (Right to Buy) | 70,200 | 3.38 | 237.3K | 0 | — | ↗ |
| 2023-08-14 | Kauffman Michael | Director | A-Award | A | Stock Option (Right to Buy) | 26,400 | 2.14 | 56.5K | 26,400 | — | ↗ |
| 2023-08-14 | Jakobovits Aya | Director | D-Return | D | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 0 | — | ↗ |
| 2023-08-14 | Healey Don | Officer | D-Return | D | Stock Option (Right to Buy) | 125,000 | 15.52 | 1.94M | 0 | — | ↗ |
| 2023-08-14 | Harvey Brian Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 28,200 | 2.14 | 60.3K | 28,200 | — | ↗ |
| 2023-08-14 | Galimi Francesco | Officer | A-Award | A | Stock Option (Right to Buy) | 73,964 | 2.14 | 158.3K | 73,964 | — | ↗ |
| 2023-08-14 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.14 | 64.2K | 30,000 | — | ↗ |
| 2023-08-14 | DUBIN STEVE | Director | D-Return | D | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 0 | — | ↗ |
| 2023-08-14 | Chodakewitz Jeffrey | Director | D-Return | D | Stock Option (Right to Buy) | 26,400 | 5.20 | 137.1K | 0 | — | ↗ |
| 2023-08-14 | Aftab Blake | Officer | A-Award | A | Stock Option (Right to Buy) | 117,200 | 2.14 | 250.8K | 117,200 | — | ↗ |
| 2023-07-10 | Peng Katie | Director | A-Award | A | Stock Option (Right to Buy) | 70,200 | 3.38 | 237.3K | 70,200 | — | ↗ |
| 2023-06-30 | DUBIN STEVE | Director | P-Purchase | A | Common Stock | 5,000 | 2.40 | 12.0K | 10,900 | — | ↗ |
| 2023-06-27 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 250,000 | 2.09 | 522.5K | 646,657 | — | ↗ |
| 2023-06-27 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 442,000 | 2.09 | 923.8K | 5,685,259 | — | ↗ |
| 2023-06-01 | Sinclair Andrew | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 5,900 | — | ↗ |
| 2023-06-01 | Sanna Bastiano | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 5,900 | — | ↗ |
| 2023-06-01 | Kauffman Michael | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 5,900 | — | ↗ |
| 2023-06-01 | Jakobovits Aya | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 5,900 | — | ↗ |
| 2023-06-01 | GORDON CARL L | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 5,900 | — | ↗ |
| 2023-06-01 | DUBIN STEVE | Director | A-Award | A | Common Stock | 5,900 | 0.00 | — | 5,900 | — | ↗ |
| 2023-06-01 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 26,400 | 5.20 | 137.1K | 26,400 | — | ↗ |
| 2023-02-15 | Healey Don | Officer | S-Sale | D | Common Stock | 4,533 | 7.57 | 34.3K | 66,568 | — | ↗ |
| 2023-02-10 | Healey Don | Officer | S-Sale | D | Common Stock | 10,467 | 7.98 | 83.5K | 71,101 | — | ↗ |
| 2023-01-24 | Schor Chen | Officer | A-Award | A | Stock Option (Right to Buy) | 384,900 | 0.00 | — | 384,900 | — | ↗ |
| 2023-01-24 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 117,200 | 0.00 | — | 117,200 | — | ↗ |
| 2023-01-24 | Harvey Brian Nicholas | Officer | A-Award | A | Common Stock | 26,100 | 0.00 | — | 84,916 | — | ↗ |
| 2023-01-24 | Galimi Francesco | Officer | A-Award | A | Common Stock | 26,100 | 0.00 | — | 88,551 | — | ↗ |
| 2023-01-24 | Aftab Blake | Officer | A-Award | A | Common Stock | 26,100 | 0.00 | — | 54,309 | — | ↗ |
| 2022-12-31 | Schor Chen | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 53,424 | — | ↗ |
| 2022-11-10 | Schor Chen | Officer | S-Sale | D | Common Stock | 9,955 | 21.03 | 209.3K | 91,469 | — | ↗ |
| 2022-11-10 | Aftab Blake | Officer | S-Sale | D | Common Stock | 6,967 | 21.00 | 146.3K | 28,209 | — | ↗ |
| 2022-11-07 | Schor Chen | Officer | S-Sale | D | Common Stock | 30,000 | 19.05 | 571.5K | 83,424 | — | ↗ |
| 2022-11-03 | Schor Chen | Officer | S-Sale | D | Common Stock | 24,813 | 18.04 | 447.7K | 113,424 | — | ↗ |
| 2022-11-02 | Schor Chen | Officer | S-Sale | D | Common Stock | 500 | 18.00 | 9.0K | 138,237 | — | ↗ |
| 2022-10-19 | Aftab Blake | Officer | S-Sale | D | Common Stock | 8,067 | 16.27 | 131.3K | 35,176 | — | ↗ |
| 2022-10-13 | Aftab Blake | Officer | F-InKind | D | Common Stock | 7,933 | 15.92 | 126.3K | 43,243 | — | ↗ |
| 2022-10-12 | Aftab Blake | Officer | S-Sale | D | Common Stock | 1,646 | 15.40 | 25.3K | 51,176 | — | ↗ |
| 2022-10-04 | Schor Chen | Officer | F-InKind | D | Common Stock | 21,288 | 14.22 | 302.7K | 101,424 | — | ↗ |
| 2022-10-04 | Healey Don | Officer | F-InKind | D | Common Stock | 7,933 | 14.22 | 112.8K | 55,468 | — | ↗ |
| 2022-10-04 | Harvey Brian Nicholas | Officer | F-InKind | D | Common Stock | 7,096 | 14.22 | 100.9K | 58,816 | — | ↗ |
| 2022-10-04 | Galimi Francesco | Officer | F-InKind | D | Common Stock | 7,933 | 14.22 | 112.8K | 62,451 | — | ↗ |
| 2022-09-14 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 952 | 18.00 | 17.1K | 138,737 | — | ↗ |
| 2022-09-13 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 3,371 | 18.01 | 60.7K | 139,689 | — | ↗ |
| 2022-09-12 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 200 | 18.00 | 3.6K | 143,060 | — | ↗ |
| 2022-09-09 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 8,094 | 16.51 | 133.6K | 66,747 | — | ↗ |
| 2022-08-04 | Schor Chen | Officer | G-Gift | A | Common Stock | 53,424 | 0.00 | — | 143,260 | — | ↗ |
| 2022-08-04 | Healey Don | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 68,934 | — | ↗ |
| 2022-08-04 | Harvey Brian Nicholas | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 70,608 | — | ↗ |
| 2022-08-04 | Galimi Francesco | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 75,917 | — | ↗ |
| 2022-08-04 | Aftab Blake | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 54,967 | — | ↗ |
| 2022-08-03 | Aftab Blake | Officer | S-Sale | D | Common Stock | 6,968 | 18.00 | 125.4K | 38,967 | — | ↗ |
| 2022-08-01 | Aftab Blake | Officer | S-Sale | D | Common Stock | 6,968 | 16.64 | 115.9K | 45,935 | — | ↗ |
| 2022-07-06 | Schor Chen | Director / Officer | G-Gift | D | Common Stock | 53,424 | 0.00 | — | 96,000 | — | ↗ |
| 2022-07-05 | Aftab Blake | Officer | S-Sale | D | Common Stock | 1,363 | 14.50 | 19.8K | 52,903 | — | ↗ |
| 2022-06-02 | Sinclair Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-02 | Sanna Bastiano | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-02 | Kauffman Michael | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-02 | Jakobovits Aya | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-02 | GORDON CARL L | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-02 | DUBIN STEVE | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 11.49 | 212.6K | 18,500 | — | ↗ |
| 2022-06-02 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-05-10 | Aftab Blake | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-04-04 | Galimi Francesco | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 1,775 | 16.82 | 29.9K | 26,625 | — | ↗ |
| 2022-04-01 | Galimi Francesco | Officer | S-Sale | D | Common Stock | 1,775 | 21.00 | 37.3K | 59,917 | — | ↗ |
| 2022-03-09 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 2,000 | 14.00 | 28.0K | 356,345 | — | ↗ |
| 2022-02-16 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 2,000 | 14.83 | 29.7K | 358,345 | — | ↗ |
| 2022-02-14 | Schor Chen | Director / Officer | F-InKind | D | Common Stock | 21,288 | 14.27 | 303.8K | 149,424 | — | ↗ |
| 2022-02-14 | Healey Don | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 58,467 | — | ↗ |
| 2022-02-14 | Harvey Brian Nicholas | Officer | F-InKind | D | Common Stock | 4,696 | 14.27 | 67.0K | 54,608 | — | ↗ |
| 2022-02-14 | Galimi Francesco | Officer | F-InKind | D | Common Stock | 5,533 | 14.27 | 79.0K | 59,917 | — | ↗ |
| 2022-02-14 | Aftab Blake | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 58,436 | — | ↗ |
| 2022-02-09 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 4,000 | 14.03 | 56.1K | 360,345 | — | ↗ |
| 2022-01-28 | Schor Chen | Director / Officer | F-InKind | D | Common Stock | 21,288 | 11.69 | 248.9K | 122,712 | — | ↗ |
| 2022-01-28 | Healey Don | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 48,000 | — | ↗ |
| 2022-01-28 | Harvey Brian Nicholas | Officer | F-InKind | D | Common Stock | 4,696 | 11.69 | 54.9K | 43,304 | — | ↗ |
| 2022-01-28 | Galimi Francesco | Officer | F-InKind | D | Common Stock | 5,533 | 11.69 | 64.7K | 49,450 | — | ↗ |
| 2022-01-28 | Aftab Blake | Officer | F-InKind | D | Common Stock | 5,564 | 11.69 | 65.0K | 42,436 | — | ↗ |
| 2022-01-07 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 295,000 | 15.52 | 4.58M | 295,000 | — | ↗ |
| 2022-01-07 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 15.52 | 1.94M | 125,000 | — | ↗ |
| 2022-01-07 | Harvey Brian Nicholas | Officer | A-Award | A | Stock Option (Right to Buy | 125,000 | 15.52 | 1.94M | 125,000 | — | ↗ |
| 2022-01-07 | Galimi Francesco | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 15.52 | 1.94M | 125,000 | — | ↗ |
| 2022-01-07 | Aftab Blake | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 15.52 | 1.94M | 125,000 | — | ↗ |
| 2022-01-05 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 2,000 | 16.90 | 33.8K | 364,345 | — | ↗ |
| 2022-01-03 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 6,000 | 18.02 | 108.1K | 366,345 | — | ↗ |
| 2021-12-31 | Jakobovits Aya | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-10 | ORBIMED ADVISORS LLC | Director / 10% Owner | A-Award | A | Common Stock | 214,285 | 14.00 | 3.00M | 242,285 | — | ↗ |
| 2021-12-10 | GORDON CARL L | Director / 10% Owner | A-Award | A | Common Stock | 214,285 | 14.00 | 3.00M | 242,285 | — | ↗ |
| 2021-12-08 | Sinclair Andrew | Director | P-Purchase | A | Common Stock | 500,000 | 14.00 | 7.00M | 2,115,385 | — | ↗ |
| 2021-11-17 | Kauffman Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-12 | Aftab Blake | Officer | — | D | Stock Option (Right to Buy) | 50,000 | 15.93 | 796.5K | 0 | — | ↗ |
| 2021-10-01 | Schor Chen | Director / Officer | A-Award | A | Common Stock | 240,000 | 0.00 | — | 240,000 | — | ↗ |
| 2021-10-01 | Healey Don | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2021-10-01 | Harvey Brian Nicholas | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2021-10-01 | Galimi Francesco | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 86,983 | — | ↗ |
| 2021-06-16 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 7,484 | 10.53 | 78.8K | 74,841 | — | ↗ |
| 2021-06-15 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 1,923 | 11.16 | 21.5K | 215,883 | — | ↗ |
| 2021-06-11 | ABBOT STEWART | Officer | A-Award | A | Non-Qualified Option (right to buy) | 5,000 | 11.75 | 58.8K | 5,000 | — | ↗ |
| 2021-06-04 | Galimi Francesco | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 6,983 | 5.97 | 41.7K | 121,441 | — | ↗ |
| 2021-06-03 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 8,982 | 12.06 | 108.3K | 98,818 | — | ↗ |
| 2021-05-20 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 900 | 14.23 | 12.8K | 217,806 | — | ↗ |
| 2021-05-19 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 612 | 13.73 | 8.4K | 89,809 | — | ↗ |
| 2021-05-18 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 3,100 | 14.06 | 43.6K | 218,706 | — | ↗ |
| 2021-05-12 | Jakobovits Aya | Director | S-Sale | D | Common Stock | 5,000 | 13.23 | 66.1K | 221,807 | — | ↗ |
| 2021-05-05 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 5,312 | 13.90 | 73.8K | 120,452 | — | ↗ |
| 2021-04-30 | Sinclair Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 8,172 | 15.93 | 130.2K | 8,172 | — | ↗ |
| 2021-04-30 | Sanna Bastiano | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 18,500 | — | ↗ |
| 2021-04-30 | Jakobovits Aya | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 18,500 | — | ↗ |
| 2021-04-30 | GORDON CARL L | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 18,500 | — | ↗ |
| 2021-04-30 | DUBIN STEVE | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 18,500 | — | ↗ |
| 2021-04-30 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 15.93 | 294.7K | 18,500 | — | ↗ |
| 2021-04-20 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 8,982 | 12.01 | 107.8K | 125,764 | — | ↗ |
| 2021-04-06 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 8,982 | 13.04 | 117.1K | 134,746 | — | ↗ |
| 2021-03-30 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 3,582 | 12.30 | 44.1K | 149,128 | — | ↗ |
| 2021-03-16 | Schor Chen | Director / Officer | S-Sale | D | Common Stock | 5,395 | 15.66 | 84.5K | 129,318 | — | ↗ |
| 2021-03-02 | Sinclair Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 28,828 | 15.75 | 454.0K | 28,828 | — | ↗ |
| 2021-02-12 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 421,600 | 16.82 | 7.09M | 421,600 | — | ↗ |
| 2021-02-12 | ORBIMED ADVISORS LLC | Director / 10% Owner | A-Award | A | Common Stock | 104,050 | 13.00 | 1.35M | 396,657 | — | ↗ |
| 2021-02-12 | Krehlik Carrie | Officer | A-Award | A | Stock Option (Right to Buy) | 11,200 | 16.82 | 188.4K | 11,200 | — | ↗ |
| 2021-02-12 | Klickstein Lloyd | Officer | A-Award | A | Stock Option (Right to Buy) | 41,100 | 16.82 | 691.3K | 41,100 | — | ↗ |
| 2021-02-12 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 30,400 | 16.82 | 511.3K | 30,400 | — | ↗ |
| 2021-02-12 | Harvey Brian Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 28,200 | 16.82 | 474.3K | 28,200 | — | ↗ |
| 2021-02-12 | Galimi Francesco | Officer | A-Award | A | Stock Option (Right to Buy) | 28,400 | 16.82 | 477.7K | 28,400 | — | ↗ |
| 2021-02-12 | GORDON CARL L | Director / 10% Owner | A-Award | A | Common Stock | 420,299 | 13.00 | 5.46M | 5,243,259 | — | ↗ |
| 2021-02-12 | Chimovits Erez | Director / 10% Owner | A-Award | A | Common Stock | 104,050 | 13.00 | 1.35M | 396,657 | — | ↗ |
| 2021-02-12 | ABBOT STEWART | Officer | A-Award | A | Stock Option (Right to Buy) | 106,900 | 16.82 | 1.80M | 106,900 | — | ↗ |
| 2021-01-25 | Schor Chen | Director / Officer | G-Gift | D | Common Stock | 27,014 | 0.00 | — | 0 | — | ↗ |
| 2021-01-13 | Schor Chen | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 240,000 | 13.27 | 3.18M | 240,000 | — | ↗ |
| 2021-01-13 | Krehlik Carrie | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 13.27 | 530.8K | 40,000 | — | ↗ |
| 2021-01-13 | Klickstein Lloyd | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 13.27 | 1.06M | 80,000 | — | ↗ |
| 2021-01-13 | Healey Don | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 13.27 | 928.9K | 70,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
9.60M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Chen Schor, MBA President and Chief Executive Officer | 646.3K | — | — | 512.1K | 284.6K | 22.8K | 1.47M | 34.94% | ↗ |
| 2 | 2025 | Julia Maltzman, M.D. Chief Medical Officer | 452.3K | — | — | 502.6K | 153.6K | 16.3K | 1.12M | 44.68% | ↗ |
| 3 | 2025 | Blake Aftab, Ph.D. Chief Scientific Officer and Senior Vice President | 484.7K | — | — | 184.4K | 155.2K | 91.2K | 915.5K | 20.14% | ↗ |
| 4 | 2024 | Chen Schor, MBA President and Chief Executive Officer | 627.6K | — | 168.7K | 3.59M | 241.8K | 18.6K | 4.64M | 80.88% | ↗ |
| 5 | 2024 | Francesco Galimi, M.D., Ph.D. Former Chief Medical Officer | 485.2K | — | 63.1K | 849.6K | — | 449.9K | 1.85M | 49.40% | ↗ |
| 6 | 2024 | Nick Harvey, MBA Chief Financial Officer | 461.7K | — | 63.1K | 849.2K | 129.4K | 20.1K | 1.52M | 59.88% | ↗ |
| 7 | 2024 | Blake Aftab, Ph.D. Chief Scientific Officer and Senior Vice President | 470.7K | — | 47.3K | 732.5K | 131.9K | 91.2K | 1.47M | 52.92% | ↗ |
| 8 | 2023 | Chen Schor President and Chief Executive Officer | 606.1K | — | 773.8K | 4.33M | 250.3K | 15.6K | 5.97M | 85.40% | ↗ |
| 9 | 2023 | Chen Schor, MBA President and Chief Executive Officer | 606.1K | — | 773.8K | 4.33M | 250.3K | 15.6K | 5.97M | 85.40% | ↗ |
| 10 | 2023 | Nick Harvey Chief Financial Officer | 445.5K | — | 236.2K | 1.30M | 133.8K | 15.6K | 2.13M | 72.10% | ↗ |
| 11 | 2023 | Nick Harvey, MBA Chief Financial Officer | 445.5K | — | 236.2K | 1.30M | 133.8K | 15.6K | 2.13M | 72.10% | ↗ |
| 12 | 2023 | Donald Healey Chief Technology Officer | 454.3K | — | 236.2K | 1.25M | 136.5K | 15.6K | 2.09M | 70.98% | ↗ |
| 13 | 2022 | Chen Schor President and Chief Executive Officer | 562.3K | — | — | 3.09M | 309.5K | 27.8K | 3.99M | 77.44% | ↗ |
| 14 | 2022 | Blake Aftab Chief Scientific Officer | 401.8K | — | — | 1.80M | 182.6K | 90.7K | 2.48M | 72.78% | ↗ |
| 15 | 2022 | Francesco Galimi Chief Medical Officer | 443.4K | — | — | 1.31M | 195.4K | 41.6K | 1.99M | 65.79% | ↗ |
| 16 | 2021 | Chen Schor President and Chief Executive Officer | 535.8K | — | 1.95M | 6.94M | 321.6K | 9.4K | 9.76M | 91.12% | ↗ |
| 17 | 2021 | Nick Harvey Chief Financial Officer | 396.8K | — | 650.4K | 1.13M | 190.6K | 9.4K | 2.38M | 74.91% | ↗ |
| 18 | 2021 | Francesco Galimi Chief Technology Officer | 412.8K | — | 650.4K | 1.04M | 198.2K | 40.3K | 2.34M | 72.17% | ↗ |
| 19 | 2021 | Francesco Galimi Chief Medical Officer | 412.8K | — | 650.4K | 1.04M | 198.2K | 40.3K | 2.34M | 72.17% | ↗ |
| 20 | 2020 | Chen Schor President and Chief Executive Officer | 499.2K | — | 815.3K | 9.71M | 212.2K | 38.7K | 11.28M | 93.35% | ↗ |
| 21 | 2020 | Lloyd Klickstein, M.D., Ph.D. Chief Innovation Officer | 397.6K | — | 280.2K | 2.20M | — | 16.7K | 2.90M | 85.70% | ↗ |
| 22 | 2020 | Francesco Galimi Chief Technology Officer | 389.2K | 162.5K | — | 821.6K | 115.8K | 38.7K | 1.53M | 53.78% | ↗ |
| 23 | 2020 | Francesco Galimi, M.D., Ph.D. Chief Medical Officer | 389.2K | 162.5K | — | 821.6K | 115.8K | 38.7K | 1.53M | 53.78% | ↗ |
| 24 | 2020 | Anil Singhal, Ph.D. Chief Executive Officer | 338.0K | — | — | 101.0K | 211.5K | 754.0K | 1.40M | 7.19% | ↗ |
| 25 | 2019 | Chen Schor President and Chief Executive Officer | 479.2K | — | 436.9K | 1.66M | 189.2K | 8.4K | 2.78M | 75.64% | ↗ |
| 26 | 2019 | Anil Singhal, Ph.D. Chief Executive Officer | 308.0K | — | — | 2.22M | 110.9K | 69.2K | 2.70M | 81.95% | ↗ |
| 27 | 2019 | Lloyd Klickstein, M.D., Ph.D Chief Scientific Officer | 248.2K | — | 150.1K | 1.93M | 77.7K | 5.9K | 2.42M | 86.27% | ↗ |
| 28 | 2019 | Lloyd Klickstein, M.D., Ph.D. Chief Innovation Officer | 248.2K | — | 150.1K | 1.93M | 77.7K | 5.9K | 2.42M | 86.27% | ↗ |
| 29 | 2019 | Joan Mannick, M.D. Chief Medical Officer | 385.0K | — | 150.1K | 699.6K | 121.7K | 8.4K | 1.36M | 62.26% | ↗ |
| 30 | 2019 | Francesco Galimi, M.D., Ph.D. Chief Medical Officer | 105.0K | 162.5K | — | 347.5K | 29.4K | 15.4K | 659.8K | 52.67% | ↗ |
| 31 | 2018 | Chen Schor President and Chief Executive Officer | 443.2K | — | — | 2.42M | 225.0K | 8.3K | 3.09M | 78.14% | ↗ |
| 32 | 2018 | Meredith Manning Chief Commercial Officer | 100.6K | — | — | 1.84M | 39.7K | 1.3K | 1.99M | 92.87% | ↗ |
| 33 | 2018 | Joan Mannick, M.D. Chief Medical Officer | 356.8K | — | — | 943.8K | 144.0K | 8.4K | 1.45M | 64.95% | ↗ |
| 34 | 2018 | Joan Mannick Chief Medical Officer | 356.8K | — | — | 943.8K | 144.0K | 8.3K | 1.45M | 64.96% | ↗ |
| 35 | 2017 | Chen Schor President and Chief Executive Officer | 268.8K | — | — | — | 209.3K | 7.4K | 485.5K | 0.00% | ↗ |
| 36 | 2017 | Joan Mannick Chief Medical Officer | 236.0K | — | — | — | 163.7K | 6.5K | 406.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Schor | Chief Executive Officer, President & Director | 888.0K | male |
| Blake Aftab | Senior Vice President & Chief Scientific Officer | 731.1K | — |
| Julie Maltzman | Chief Medical Officer | 622.2K | — |
| Brian Nicholas Harvey | Chief Financial Officer | 611.1K | male |
| Donald Healey | Chief Technology Officer | 606.3K | — |
| Amy Locke | Chief Human Resource Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACET
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
